NasdaqGM:CRSPBiotechs
Is CRISPR Therapeutics (CRSP) Near Fair Value With $2.4B In Cash?
CRISPR Therapeutics stock has given up around 60% over the past five years, yet recent checks suggest it now sits closer to a fair, middle-of-the-road valuation rather than being clearly cheap or clearly expensive.
Over five years the share price has declined about 60%, which sets expectations low and puts more focus on whether the current valuation fairly reflects the company’s prospects.
Strong cash reserves of about US$2.4b and a growing gene editing pipeline can support long development...